trending Market Intelligence /marketintelligence/en/news-insights/trending/AudRlrorDRfgRXiBDNkHCQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GSK-backed ViiV files for EMA approval of fostemsavir to treat HIV-1

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


GSK-backed ViiV files for EMA approval of fostemsavir to treat HIV-1

ViiV Healthcare Ltd. filed an application with the European Medicines Agency seeking approval of its medicine fostemsavir to treat HIV-1 patients who no longer respond to other therapies.

The U.K.-based company — majority-owned by GlaxoSmithKline PLC, with Pfizer Inc. and Shionogi & Co. Ltd. as shareholders — is developing fostemsavir for use in combination with other antiretroviral drugs to treat adults with multidrug-resistant HIV-1 infection who do not show virus suppression due to resistance or intolerance to other drugs.

The EMA has granted fostemsavir an accelerated assessment, which reduces the time taken to review products for marketing approval.

On Dec. 5, 2019, ViiV filed for approval of the drug with the U.S. Food and Drug Administration. The FDA has granted the medicine fast-track and breakthrough-therapy tags to facilitate and speed up its development.

In July 2019, data from the late-stage Brighte study showed that fostemsavir helped suppress the HIV-1 virus in patients who had been heavily treated in the past.